Please find enclosed herewith audited financial results for the quarter and year ended on 31 March 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Genomic Valley Biotech Ltd published its audited standalone financial results for the quarter and year ended March 31, 2026 via a newspaper advertisement in Financial Express (English) and Jansatta (Hindi) on May 31, 2026, as required under SEBI LODR Regulation 47. For full-year FY26, net profit after tax collapsed to roughly ₹3.03 lakh compared to about ₹35.6 lakh in FY25, a steep year-on-year decline. Total income from operations fell sharply from around ₹84.4 lakh in FY25 to about ₹26.75 lakh in FY26. The company slipped into a loss in Q4 FY26, reporting a net loss after tax of ₹81,745 against a loss of ₹8.35 lakh in Q4 FY25. Basic EPS dropped to ₹0.10 for FY26 from ₹1.17 in FY25. The results were reviewed by the Audit Committee and approved by the Board on May 29, 2026.
The filing confirms a significant deterioration in both top-line and bottom-line performance, with the company reporting a quarterly loss and full-year profit shrinking by over 90%. Shareholders should view this as a negative signal on near-term earnings momentum, though the very small absolute scale of the business means the stock may remain thinly traded and volatile.